On October 3, 2024, the US Food and Drug Administration (FDA) revised its shortage categorization of tirzepatide, a glucagon-like peptide 1 (GLP-1) medication, marking the shortage as “resolved ...

In a reversal, the Food and Drug Administration (FDA) said it will allow some compounding pharmacies to temporarily make their own versions of tirzepatide, the active ingredient in Eli Lilly’s ...

Mounjaro is a prescription drug with the active ingredient tirzepatide. It helps regulate blood sugar and may help reduce weight in people with type 2 diabetes. Here, we look at how to get Mounjaro.

Eli Lilly's dual GLP-1/GIP agonist tirzepatide has been shown to reduce the risk of worsening disease in people with heart failure and obesity in a phase 3 trial, the first to show a benefit on ...

The drug uses the active ingredient tirzepatide and was approved by the FDA in May 2022 for type 2 diabetes; although McCaskill said her blood sugar was elevated, she didn’t have diabetes ...

Compounding pharmacies are suing the Food and Drug Administration so they can keep making imitation versions of popular—and lucrative—tirzepatide drugs, namely knockoffs of Mounjaro for ...

,A weight-loss drug more effective than Ozempic and Wegovy has recently been approved in Australia. The drug, tirzepatide, is sold under the brand name Mounjaro and affects feelings of hunger and ...

On October 2, the US Food and Drug Administration (FDA)'s Drug Shortage Database showed that the tirzepatide injection (Zepbound, Mounjaro/Lilly) shortage is now "resolved." The agency wrote in a ...

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and obese ...

Nearly 250,000 people in England could access a weight loss injection on the NHS. Tirzepatide is prescribed for type 2 diabetes, but has been shown in clinical trials to be effective for weight loss.